Fiche publication
Date publication
novembre 2024
Journal
Blood advances
Auteurs
Membres identifiés du Cancéropôle Est :
Pr RUBIO Marie Thérèse
,
Dr PAGLIUCA Simona
Tous les auteurs :
Luque Paz D, Gagelmann N, Benajiba L, Riou J, Salit RB, Orvain C, Schroeder T, Bories C, Gurnari C, Badbaran A, Boyer-Perrard F, Pagliuca S, Rautenberg C, Tavitian S, Panagiota V, Ianotto JC, Thol FR, Cayssials E, Heuser M, Rubio MT, Cassinat B, Daltro de Oliveira R, Sauter CS, Maciejewski JP, Reinhardt HC, Scott BL, Ugo V, Kröger N, Kiladjian JJ, Robin M
Lien Pubmed
Résumé
The aim of our study was to analyze the potential survival benefit associated with HSCT according to clinico-biological scores which incorporate molecular data (MIPSS70 and MIPSS70+V2) to facilitate decision-making in this context. One transplant (n=241) and one non-transplant cohorts (n=239) were used to test the hypothesis that PMF patients with higher risk molecular score benefit from HSCT. A weighted propensity score was applied to balance confounding factors with the transplanted cohort as reference. Weighted Cox proportional hazard models and logistic regression analyses were performed. 105 non-transplanted patients could be matched to the 239 transplanted patients. Mean age in transplanted and non-transplanted matched patients was 55.5 and 57.9 years. Blood cell count and DIPSS score distribution were similar in both groups. HSCT was associated with a higher 6-year OS rate in intermediate-2 (60.1% versus 41.5%) and high-risk DIPSS patients (44.4% versus 6.55%), high-risk MIPSS70 (46.5 versus 23.9%), high-risk (73.2% versus 39.7%) or very high-risk MIPSS70V2 (51.8% versus 24%). Intermediate MIPSS70 patients have an advantage of survival with HSCT only when their MTSS were low or intermediate. Transplanted patients had an increased mortality risk the first year but a significant benefit with HSCT after the one-year landmark was observed in higher risk patients. This study confirms that similar to DIPSS, MIPSS70 and MIPSS70+V2 risk score in addition to MTSS can be used to determine which patients with primary myelofibrosis have survival benefit from HSCT over non-HSCT strategies.
Référence
Blood Adv. 2024 11 19;:
